(Q37289781)

19 August 2017

1 reference

title

Obesity, low testosterone levels and erectile dysfunction (English)

1 reference

19 August 2017

0 references

1 reference

1 reference

M Diaz-Arjonilla

1

1 reference

19 August 2017

M Schwarcz

series ordinal

2

1 reference

19 August 2017

R S Swerdloff

series ordinal

3

1 reference

19 August 2017

C Wang

series ordinal

4

1 reference

19 August 2017

language of work or name

1 reference

9 October 2008

1 reference

International Journal of Impotence Research

19 August 2017

1 reference

19 August 2017

21

1 reference

19 August 2017

89-98

1 reference

19 August 2017

2

1 reference

https://scigraph.springernature.com/pub.10.1038/ijir.2008.42

19 August 2017

0 references

cites work

Metabolic liver disease of obesity and role of adipose tissue in the pathogenesis of nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.42

Androgen deficiency, diabetes, and the metabolic syndrome in men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.42

A simple self-report diary for assessing psychosexual function in hypogonadal men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.42

Sexual function in men older than 50 years of age: results from the health professionals follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.42

Prevalence and Trends in Obesity Among US Adults, 1999-2000

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.42

7 January 2021

Prevalence of overweight and obesity in the United States, 1999-2004

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.42

7 January 2021

Cause-specific excess deaths associated with underweight, overweight, and obesity

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.42

7 January 2021

Overweight and obesity in the United States: prevalence and trends, 1960-1994

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.42

7 January 2021

Childhood body-mass index and the risk of coronary heart disease in adulthood

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.42

7 January 2021

Adolescent overweight and future adult coronary heart disease

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.42

7 January 2021

Low serum testosterone and sex-hormone-binding-globulin in massively obese men.

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.42

7 January 2021

Lifestyle and nutritional determinants of bioavailable androgens and related hormones in British men.

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.42

7 January 2021

Body mass index in relation to semen quality and reproductive hormones among 1,558 Danish men.

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.42

7 January 2021

Epidemiology: testosterone and the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.42

7 January 2021

Body composition, metabolic syndrome and testosterone in ageing men.

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.42

7 January 2021

Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: correlations with bioavailable testosterone and visceral adiposity

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.42

7 January 2021

Thematic review series: adipocyte biology. Adipose tissue function and plasticity orchestrate nutritional adaptation.

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.42

7 January 2021

Inflammation and insulin resistance

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.42

7 January 2021

Metabolic syndrome: from global epidemiology to individualized medicine

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.42

7 January 2021

The metabolic syndrome: how to approach differing definitions

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.42

7 January 2021

Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.42

7 January 2021

Adiponectin in health and disease

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.42

7 January 2021

Adiponectin and the metabolic syndrome: mechanisms mediating risk for metabolic and cardiovascular disease

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.42

7 January 2021

Adiponectin, obesity and atherosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.42

7 January 2021

Adiponectin and adiponectin receptors

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.42

7 January 2021

Role of leptin in the cardiovascular and endocrine complications of metabolic syndrome.

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.42

7 January 2021

Adipocytokines and insulin resistance

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.42

7 January 2021

Current controversies in testosterone testing: aging and obesity

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.42

7 January 2021

Sex steroid hormones, sex hormone-binding globulin, and obesity in men and women

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.42

7 January 2021

Increased Estrogen Production in Obese Men*

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.42

7 January 2021

Association of bioavailable, free, and total testosterone with insulin resistance: influence of sex hormone-binding globulin and body fat.

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.42

7 January 2021

Visceral and Subcutaneous Adipose Tissue Assessed by Magnetic Resonance Imaging in Relation to Circulating Androgens, Sex Hormone-Binding Globulin, and Luteinizing Hormone in Young Men

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.42

7 January 2021

Relative androgen deficiency in relation to obesity and metabolic status in older men.

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.42

7 January 2021

Sex hormones, inflammation and the metabolic syndrome: a population-based study

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.42

7 January 2021

Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men.

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.42

7 January 2021

The metabolic syndrome and smoking in relation to hypogonadism in middle-aged men: a prospective cohort study

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.42

7 January 2021

HYPOGONADISM AND METABOLIC SYNDROME: IMPLICATIONS FOR TESTOSTERONE THERAPY

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.42

7 January 2021

Obesity, fat distribution and infertility

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.42

7 January 2021

Increasing insulin resistance is associated with a decrease in Leydig cell testosterone secretion in men.

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.42

7 January 2021

Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men.

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.42

7 January 2021

Acute sex steroid withdrawal reduces insulin sensitivity in healthy men with idiopathic hypogonadotropic hypogonadism.

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.42

7 January 2021

The effects of varying doses of T on insulin sensitivity, plasma lipids, apolipoproteins, and C-reactive protein in healthy young men.

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.42

7 January 2021

Association of hypogonadism and type II diabetes in men attending an outpatient erectile dysfunction clinic

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.42

7 January 2021

NCEP-ATPIII-defined metabolic syndrome, type 2 diabetes mellitus, and prevalence of hypogonadism in male patients with sexual dysfunction

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.42

7 January 2021

Partial androgen deficiency in aging type 2 diabetic men and its relationship to glycemic control

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.42

7 January 2021

Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.42

7 January 2021

Contrasting testosterone concentrations in type 1 and type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.42

7 January 2021

Obesity and sexual dysfunction, male and female

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.42

7 January 2021

Erectile dysfunction as a predictor of the metabolic syndrome in aging men: results from the Massachusetts Male Aging Study

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.42

7 January 2021

Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference).

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.42

7 January 2021

Heart disease risk factors predict erectile dysfunction 25 years later: the Rancho Bernardo Study

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.42

7 January 2021

Erectile dysfunction is a marker for cardiovascular disease: results of the minority health institute expert advisory panel

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.42

7 January 2021

AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.42

7 January 2021

Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men.

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.42

7 January 2021

Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.42

7 January 2021

Erectile dysfunction and coronary risk factors: prospective results from the Massachusetts male aging study

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.42

7 January 2021

Modifiable risk factors and erectile dysfunction: can lifestyle changes modify risk?

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.42

7 January 2021

Health issues of men: prevalence and correlates of erectile dysfunction

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.42

7 January 2021

Is obesity an underlying factor in erectile dysfunction?

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.42

7 January 2021

Central obesity is an independent predictor of erectile dysfunction in older men.

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.42

7 January 2021

Effect of life-style factors on incidence of erectile dysfunction

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.42

7 January 2021

The natural progression and remission of erectile dysfunction: results from the Massachusetts Male Aging Study

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.42

7 January 2021

Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.42

7 January 2021

Is there a relationship between sex hormones and erectile dysfunction? Results from the Massachusetts Male Aging Study

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.42

7 January 2021

Androgen deficiency and abnormal penile duplex parameters in obese men with erectile dysfunction

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.42

7 January 2021

Incidence of metabolic syndrome and insulin resistance in a population with organic erectile dysfunction

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.42

7 January 2021

Prevalence of metabolic syndrome and its association with erectile dysfunction among urologic patients: metabolic backgrounds of erectile dysfunction.

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.42

7 January 2021

Psychobiologic correlates of the metabolic syndrome and associated sexual dysfunction.

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.42

7 January 2021

A comparison of NCEP-ATPIII and IDF metabolic syndrome definitions with relation to metabolic syndrome-associated sexual dysfunction.

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.42

7 January 2021

Gonadal and erectile dysfunction in diabetics

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.42

7 January 2021

Association of specific symptoms and metabolic risks with serum testosterone in older men

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.42

7 January 2021

Does testosterone have a role in erectile function?

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.42

7 January 2021

Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T.

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.42

7 January 2021

The administration of pharmacological doses of testosterone or 19-nortestosterone to normal men is not associated with increased insulin secretion or impaired glucose tolerance.

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.42

7 January 2021

Effect of 2 years of testosterone replacement on insulin secretion, insulin action, glucose effectiveness, hepatic insulin clearance, and postprandial glucose turnover in elderly men.

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.42

7 January 2021

Do reproductive hormones modify insulin sensitivity and metabolism in older men? A randomized, placebo-controlled clinical trial of recombinant human chorionic gonadotropin

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.42

7 January 2021

Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.42

7 January 2021

Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.42

7 January 2021

The effect of testosterone replacement therapy on adipocytokines and C-reactive protein in hypogonadal men with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.42

7 January 2021

Androgens stimulate myogenic differentiation and inhibit adipogenesis in C3H 10T1/2 pluripotent cells through an androgen receptor-mediated pathway

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.42

7 January 2021

The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men.

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.42

7 January 2021

Identifiers

DOI

10.1038/IJIR.2008.42

1 reference

19 August 2017

1 reference